Introduction {#Sec1}
============

Antibiotic therapy has produced unquestionable advances in the management of patients with cancer, a population with intrinsically higher risk of bacterial infection as a result of malignancy or treatment-related immune suppression.

While antimicrobial therapy has markedly reduced morbidity and mortality stemming from infection, the effects of broad-spectrum antibiotics on commensal, non-pathogenic bacterial species have remained for a long time an under-appreciated effect of this therapeutic class of drugs.

The gut microbiota, source of over 100 trillion bacteria, exists in a condition of mutually beneficial relationship with the host. Commensal bacteria are provided with a niche to colonise the host in return for their participation in the digestion of nutrients and xenobiotics, protection from pathogens and shaping of the host's immune system subsets. Derangement of this delicate relationship has been increasingly well-characterised in the context of tumour-specific immune tolerogenesis \[[@CR1]\].

Multiple levels of evidence now support the link between sensitivity to immunotherapy, taxonomic diversity and enrichment in specific gut bacterial taxa, suggesting that some species or species consortia provide intrinsic immune-modulating properties. The landmark study by Gopalakrishnan \[[@CR2]\] demonstrated how broader stool bacterial diversity and higher representation of *Ruminococcaceae* communities including *Faecalibacterium* positively influences patients' survival following ICPI by promoting a strongly immune-reactive microenvironment and lower systemic release of pro-inflammatory cytokines \[[@CR3]\]. Many other commensal bacteria have subsequently been recognised to play a similar role including *Bifidobacteria* spp., a saccarolytic Gram-positive genus highly represented within the gut that facilitates dendritic cell maturation and increased accumulation of antigen-specific T-cells within the tumour microenvironment \[[@CR4]\]. Similarly, the presence of the anaerobic commensal *Akkermansia Muciniphila* is more common in responders to ICPI, who display higher peripheral CD4 and CD8 memory T-cell responses to this bacterium \[[@CR5]\].

Antibiotic (ATB) therapy imposes profound and protracted changes to the taxonomic diversity of the host microbial ecosystem, affecting the composition of up to 30% of the bacterial species in the gut microbiome \[[@CR6]\], consequently leading to loss of microbial functions that are protective for the host. Such changes in gut microbial communities are rapid and pervasive, occurring within days from the first antibiotic dose \[[@CR7]\] and persisting for up to several months after completion of therapy \[[@CR8]\].

Mounting evidence from epidemiological studies has underscored the detrimental role of antibiotics in ICPI outcome, with exposure to antibiotics having been linked to shortened progression-free, overall survival and reduced response rates in patients receiving ICPI as part of clinical trials and in routine practice (Table [1](#Tab1){ref-type="table"}). In a previous study, we demonstrated time-dependence of antibiotics exposure as a strong, tumour-agnostic determinant of outcome in ICPI recipients, confirming prior, but not concurrent antibiotic therapy as doubling the risk of primary progression to immunotherapy and leading to a \> 20-months shortening in patients' survival independent of established prognostic factors and corticosteroid use \[[@CR10]\]. Whilst mirroring pre-clinical evidence, where antibiotic pre-conditioning ahead of tumour implantation leads to impaired responses to ICPI in mice \[[@CR26], [@CR27]\], the expanding body of clinical studies has so far painted an incomplete picture as to the mechanistic foundations underlying the relationship between ATB and immunotherapy, a point of greater consequence given the potential practice-influencing implications of ATB prescribing in the clinic. Table 1The relationship between antibiotic exposure and outcomes from immune checkpoint inhibitor therapyStudyTumour SitesICPI\
(n, %)ATB exposureATB DurationATB TypeAdministration routeResponseSurvivalNotesDerosa L et al. \[[@CR9]\]NSCLC (239)PD-L1 (205, 86%)PD-L1/ CTLA-4 (34, 14%)pATB (within 30 days)(48, 20%)No ATB (191, 80%)≤ 7 days(35, 73%)\>  7 days(13, 27%)Beta-lactam(15, 32%)Quinolones(14, 29%)Macrolides(4, 8%)Sulfonamides (12, 25%)Tetracyclines(1, 2%)Nitromidazole (1, 2%)Others(1, 2%)Oral(42, 87%)IM/ IV(5, 11%)Unreported(1, 2%)**PD** in 52% exposed vs in 43% unexposed, *P* = 0.26ATB vs no ATB**median OS**:7.9 months vs 24.6 months,HR 4.4, 95% CI 2.6--7.7, *P* \< 0.01**median PFS:**1.9 months vs 3.8 months, HR 1.5, 95%CI 1.0--2.2, *P* = 0.03Significant impact supported by multivariate analysisRCC (121)PD-L1 (106, 88%)PD-L1/CTLA-4(10, 8%)PD-L1/Bevacizumab (5, 4%)pATB (within 30 days) (16, 13%)No ATB (105, 87%)≤ 7 days(8, 50%)\>  7 days(8, 50%)Beta-lactam(13, 82%)Quinolones(1, 6%)Tetracyclines(1, 6%)Aminoglycosides (1, 6%)Oral(15, 94%)IV/ IM(1, 6%)**PD** in 75% exposed vsin 22% unexposed, *P* \< 0.01ATB vs no ATB**median OS:**17.3 months vs 30.6 months, HR 3.5, 95% CI 1.1--10.8, *P* = 0.03**median PFS:**1.9 months vs 7.4 months, HR 3.1, 95% CI 1.4--6.9, *P* \< 0.01Pinato DJ et al. \[[@CR10]\]NSCLC(119, 60%)Melanoma (38, 20%)Renal(27, 14%)Head & neck(10, 5%)Total *n* = 196PD-1/PD-L1(189, 96%)pATB (29, 15%)(within 30 days)cATB (during ICPI therapy until cessation) (68, 35%)no ATB(99, 50%)**pATB**≤7 days(26, 90%)\>  7 days(3, 10%)**cATB**≤7 days(39, 88%)**pATB**Beta-lactamin 22, 75%**cATB**Beta-lactamin 49, 72%**--pATB:PD** in 80% exposed vs 44% unexposed, *p* \< 0.001**cATB:PD** in 50% exposed vs 49% unexposed, *p* = 0.87pATB (*p* \< 0.001) but not cATB (*p* = 0.76) predicted worse OS (26 vs 2 months, HR 7.4, 95% CI 4.2--12.9) Multivariate analysis confirmed pATB as a predictor of OS (HR 3.4, 95%CI 1.9--6.1 *p* \< 0.001)ICPI-refractory in 81% pATB vs 44% no pATB, *p* \< 0.001Hakozaki T et al. \[[@CR11]\]NSCLC (90)PD-1 (90)pATB(13, 14%)(30 days before ICPI initiation)no pATB (77, 86%)≤7 days (1, 8%)\>  7 days (12, 92%)Beta-lactam (8, 61%) Sulfonamides (4, 31%)Quinolones (1, 8%)Oral(10, 77%)IV(3, 23%)--pATB vs no ATB**median PFS:**1.2 \[95% CI, 0.5--5.8\] vs 4.4 months \[95% CI, 2.5--7.4\], *P* = 0.04**median OS:**8.8 months vs not reached, *P* = 0.037Unsupported by multivariate analysis of pATB and OS:HR 2.02, (95% CI, 0.7--5.83, *P* = 0.19)Galli G et al. \[[@CR12]\]NSCLC (157)PD-1 (98, 62.4%)PD-L1 (52, 33%)CTLA4 (1, 0.6%)PD-L1/CTLA4 (6, 4%)ATB:in EIOP (27, 17%)in WIOP (46, 29%)No ATB (111, 71%)High AIER23 (15%)Low AIER(134, 85%)Median duration7.0 days (5.0--33.0)Quinolone (33, 72%)Macrolide (8, 17%)Beta-lactam (14, 30%)Rifaximin (4, 8.7%)Oral(44, 98%) IM(3, 6.5%), IV(2, 4.4%).Exposed in EIOP**RR**: 11.1% vs 24.6%, *p* = 0.20; **DCR**: 51.9% vs 56.2%, *p* = 0.8319.**AIER (high vs low)RR**: 8.7%, vs 26.6%. *p* = 0.11**DCR**: 47.8% vs 56.0%, *p* = 0.50,High vs low AIER**median PFS:**1.9 \[95% CI, 1.3--3.0\] vs3.5 months \[95% CI, 2.6--5.0\] *p* \< 0.0001**median OS:**5.1 \[95% CI, 3.8--5.9\] vs 13.2 months \[95% CI, 9.9--5.9\] *p* = 0.0004Exposed vs unexposed in EIOP**median PFS:**2.2 \[95% CI, 1.8--3.2\] vs 3.3 months \[95% CI, 2.6--4.8\]*P* = 0.1772**median OS:**11.9 \[95% CI, 9.2--15.6\] vs 5.9 months \[95% CI, 4.5--22.5\]*P* = 0.2492Significant impact supported by multivariate analysisAhmed J et al. \[[@CR13]\]NSCLC (34, 57%)Renal (4, 7%)HCC (5, 8%)Urothelial (5, 8%)Other (12 20%)Total *n* = 60ICPI with chemotherapy (8, 13%)PD-1 (49, 82%)PD-L1 (3, 5%)pATB or cATB (2 weeks before or after ICPI initiation)(17, 28%)No ATB (43, 72%)8--14 daysBeta-lactam (14, 82%)Quinolone (5, 29%)Vancomycin (7, 41%)Daptomycin (1, 6%)Linezolid (2, 12%)Meropenem (3, 18%)Tetracyclines (2, 12%)Bactrim (1, 6%)Azithromycin (1, 6%)Nitrofurantoin (1, 6%)**--RR**: 29.4% in exposed vs 62.8% in unexposed,*p* = 0.024Decreased **PFS** with ATBHR 1.6; 95% CI: 0.84--3.03, *p* = 0.048**Median OS:**24 in exposed vs 89 months in unexposed *p* = 0.003Narrow-spectrum ATB alone did not affect the RR, but broad-spectrum ATB decreased RR (*p* = 0.02) and PFS (*p* = 0.012).Multivariate analysis found that only ATB decreased RR (*p* = 0.0038) and PFS (*p* = 0.01)Tinsley N et al. \[[@CR14]\]Melanoma (206, 66%)NSCLC (56, 18%)Renal (46, 15%)Total *n* = 303--pATB or cATB (2 weeks before or 6 weeks after ICPI initiation) (94,31%)--The commonest ATBs: beta-lactam and macrolides----ATB vs no ATB**PFS**97 (95% CI 84--122) vs 178 days (95% CI 155--304) *p* = 0.049**OS**317 days (95% CI 221--584) vs 651 days (95% CI 477--998) *p* = 0.001.Cumulative ATB (\>  10 days, multiple concurrent/successive courses) further shortened PFS to 87 days (95% CI 83--122) *p* = 0.0093 and OS to 193 days (95% CI 96--355) *p* = 0.00021pATB exposed had shorter PFS and OS than cATB exposed (HR 1.37, *p* = 0.29 and HR 1.72, *p* = 0.08)Khan U et al. \[[@CR15]\]Lung (111, 46%)Bladder (36, 15%)Renal (35, 14%)GI (16, 7%)Other (44, 18%)Total *n* = 242PD-1 (189, 78%)PD-L1 (52, 21%)75, 46 and 32% received ATBs within 6 months, 60 days and 30 days of starting ICPIs------cATB use in the first 30- or 60-days of ICPI therapy associated with inferior **ORR**(OR 0.40, *p* = 0.01 and OR 0.42, *p* = 0.005, respectively)**--**pATB or cATB use in the first 6 months of ICPI use had no impactRouty B et al. \[[@CR5]\]NSCLC (140, 56%), RCC (67, 27%)urothelial carcinoma (42, 17%)Total *n* = 249PD-1/PD-L1 (249, 100%)pATB or cATB(2 months before or 1 month after ICPI initiation)(69, 28%)no ATB (180, 72%)--β-lactam+/− inhibitors, fluoroquinolonesor macrolidesMostly oral--ATB vs no ATBFor all groups combined**median PFS:**3.5 vs 4.1 months*p* = 0.017**median OS:**11.5 vs 20.6 months*p* \< 0.001For individual cancer groups,PFS and/or OS were also shorter in ATB groupUnivariate and multivariate Cox regression analyses confirmed the negative impact of ATB, independent from other factorsMielgo-Rubio X et al. \[[@CR16]\]NSCLC (168)PD-1 (168,100%)pATB or cATB(2 months before or 1 month after ICPI initiation)(47.9%)No ATB(52.1%)----Oral (70%) IV (30%)--ATB vs no ATB**OS:**8.1 (95%CI 3.6--12.5) vs 11.9 months (95%CI 9.1--14.7) *p* = 0.026**PFS:**5 (95%CI 3.1--6.9) vs 7.3 months (95%CI 2--12) *p* = 0.028IV ATB had a more negative impact than oral ATB**OS:**2.9 (95%CI, 1.6--4.1) vs 14.2 months (95%CI, 7.9--20.6) *p* = 0.0001**PFS:**2.2 (95%CI 0.6--3.7) vs 5.9 months (95%CI 3.9--8) *p* = 0.001Ouaknine J et al. \[[@CR17]\]NSCLC (72)PD-1 (72,100%)pATB or cATB (2 months before or 1 month after ICPI initiation)(30, 42%)No ATB (42, 58%)Median duration 9.5 days (IQR 7--14)The commonest ATBs:β-lactam and vancomycinMostly oral (65%)ATB vs no pATB**ORR**37% vs 24% *p* = 0.276 **Clinical benefit rate** 27% vs 29% *p* = 0.859ATB vs no ATB**median OS:** 5.1  (IQR 3.4-not reached) vs 13.4 months (IQR 10.6-not reached) *p* = 0.03**median PFS:**2.8(IQR 1.4--5.1) vs 3.3 months (IQR 1.8--7.3) *p* = 0.249--Kaderbhai C et al. \[[@CR18]\]NSCLC (74)PD-1 (74, 100%)pATB(within 3 months) (15, 20%)No ATB(59, 80%)------No difference in ORR*p* = 0.75No difference in **PFS** and *p* = 0.72,--Zhao S et al. \[[@CR19]\]NSCLC (109)PD-1 (57, 52%)PD-1/ chemotherapy (33, 30%)PD-1/apatinib or bevacizumab (19, 18%)pATB or cATB (1 month before or after ICPI initiation) (20, 18%)No ATB (89, 82%)--The commonest ATBs:β-lactam inhibitors and fluoroquinolones--Higher **PD** rates in ATB-treated group (*p* = 0.092)ATB decreased **PFS**, *p* \< 0.0001and **OS**, *p* = 0.0021In multivariable analysis, ATB was associated with shorter PFS (HR = 0.29, 95%CI 0.15--0.56, *p* \< 0.0001) and OS (HR = 0.35, 95%CI 0.16--0.77, *p* = 0.009)Thompson et al. \[[@CR20]\]NSCLC (74)PD-1 (74, 100%)pATB (within 6 weeks) (18, 24%)No ATB (56, 76%)--Mostly fluoroquinolones (50%)--ORR in ATB vs no ATB groups25% vs 23% (adjusted OR 1.2, *p* = 0.20).ATB vs no ATB**PFS**2.0 vs 3.8 months*p* \< 0.001)**OS**4.0 vs 12.6 months, *p* = 0.005The impact of ATB on PFS and OS was independent of other factors (HR 2.5, *p* = 0.02), (HR 3.5, *p* = 0.004), respectivelyDerosa L et al. \[[@CR21]\]RCC (80)PD1/PD-L1 (67, 84%),PD-1/CTLA-4 (10, 12%)PD-L1/ bevacizumab (3, 4%)pATB(within 1 month)(16, 20%)No ATB (64, 80%)--Mostly β-lactam and fluoroquinolones--Lower **ORR** in ATB group vs no ATB *p* \< 0.002ATB vs no ATB**PFS**2.3 vs. 8.1 months, *p* \< 0.001Confirmed by multivariate analysisDo TP et al. \[[@CR22]\]Lung (109)PD-1 (109, 100%)pATB or cATB(1 month before ICPI or concurrently)(87, 80%)No ATB (22, 20%)--β-lactam(12, 13.8%) quinolones(11,12.6%)other(7, 8.1%) multiple antibiotics(57, 65.5%)----ATB vs no ATB**OS**5.4 vs 17.2 months(HR 0.29, 95% CI 0.15--0.58 *p* = 0.0004)Elkrief A et al. \[[@CR23]\]Melanoma (74)PD-1 (54, 73%)CTLA-4 (5, 6.8%)CTLA-4/ carboplatin/paclitaxel (15, 20%)pATB(within 1 month)(10, 13.5%)No ATB(64, 86.5%)\> 7 days (7, 70%)\< 7 days (3, 30%)Mostly β-lactams± inhibitorsOral (40%)IV (60%)**ORR**ATB vs no ATB0% vs 34%ATB vs no ATB**median PFS**2.4 vs 7.3 months(HR 0.28, 95% CI 0.10--0.76*p* = 0.01)**median OS**10.7 vs 18.3 months(HR: 0.52, 95% CI 0.21--1.32*p* = 0.17).The multivariate analysis supported the impact of ATB on PFS(HR 0.32 (0.13--0.83) 95% CI, *p* = 0.02).Huemer F et al. \[[@CR24]\]NSCLC (30)PD-1 (30, 100%)pATB or cATB(1 month before or 1 month after ICPI initiation)(11, 37%)No ATB(19, 63%)--β-lactam (7, 64%), fluoroquinolones (4, 36%) and carbapenems (2, 18%)----ATB vs no ATB**median PFS**3.1 vs 2.9 months, (HR = 0.46 95%CI: 0.12--0.90 *p* = 0.031). **median OS** 15.1 vs 7.5 months (HR = 0.31 95%CI: 0.02--0.78 *p* = 0.026).The multivariate analysis supported the impact of ATB on PFS (*p* = 0.028) and OS (*p* = 0.026).Lalani A et al. \[[@CR25]\]RCC (146)PD-1/PD-L1 (146, 100%)pATB or cATB(2 months before or 1 month after ICPI initiation) (31, 21%)No ATB(115, 79%)------ATB vs no ATB**ORR**12.9 vs 34.8%*p* = 0.026ATB vs no ATB2.6 (1.7--5.3) vs8.1 (5.6--10.9) months*p* = 0.008--Abbreviations: *EIOP* (Early Immunotherapy Period): antibiotics given between 1 month before and 3 months after starting immunotherapy, *WIOP* (Whole immunotherapy Period): antibiotics given throughout immunotherapy, cumulative exposure to antibiotics; AIER defined as "days of antibiotic therapy/days of immunotherapy': AIER stratified over the median (4.2%) into high and low AIER groups, *RR* Response rate, *DCR* Disease control rate, *GI* Gastrointestinal, *ORR* Overall response rate, *IV* Intravenous, *IM* Intramuscular

Most of the studies highlighting the importance of a healthy gut microbial environment as a pre-requisite for ICPI response were unfortunately characterised by insufficient data on preceding or concomitant antibiotic exposure, making it impossible to disentangle the role of antibiotic-induced perturbation of the gut ecosystem in influencing clinically meaningful outcomes in these patients \[[@CR3]\].

Mechanistically, the breadth and depth of downstream effects produced by antibiotics within the cancer-immune synapse are an important challenge in studying this prognostically adverse relationship. On one hand, the direct bacteriostatic/bactericidal effect of antibiotics can cause selective pressure within the host microbial ecosystem and instigate an alternative microbiota state characterised, amongst other traits, by downregulation of major histocompatibility complex (MHC) class I/II genes and impaired effector T-cell responses, immunologic traits implicated in reduced responsiveness to ICPI \[[@CR28]\].

ATB-induced depletion of gut bacteria can also shift the repertoire of microbial-associated molecular patterns (MAMPS). These molecules signal through mucosal innate immune cells primarily via toll-like receptors (TLRs) and NOD1 \[[@CR29]\] to influence neutrophil priming, reduce local cytokine release and prime adaptive immunity by influencing the expression of MHC genes within the intestinal mucosa and reduce immunoglobulin secretion \[[@CR30]\]. Antibiotic treatment impairs TH~1~/TH~17~ responses in tumour-bearing mice through direct pre-conditioning of the gut microbiota, reducing the efficacy of cyclophosphamide-mediate immune-rejection of the tumour \[[@CR31]\]. In addition, antibiotics can also reduce the capacity of adoptively transferred CD8+ T-cells to mediate a tumour-specific response through altered LPS/TLR4 signaling in lymphodepleted mice \[[@CR32]\].

By disrupting the gut ecosystem, antibiotics instigate downstream metabolic alterations within the microenvironment with complex repercussions to the tumour-host-microbe interface. Amongst them, changes in the availability of short-chain fatty acids produced by *Akkermansia, Faecalibacteria* and *Enterococcus* from the catabolism of non-digestible carbohydrates and the conversion of primary bile acids to secondary bile acids (including deoxycholate) mediated by *Clostridiales* can significantly alter gut homeostasis and lead to profound and clinically meaningful immune-modulatory consequences \[[@CR33]\]. The immune-metabolic repercussions secondary to gut dysbiosis, potentially reversible by oral *Akkermansia* supplementation \[[@CR34]\], might explain the influence of body mass index in determining response to ICPI \[[@CR35], [@CR36]\].

With improved characterization of immune-microbiologic underpinning of the relationship between antibiotics and ICPI outcome, a key question now is whether disruption of a well-equilibrated gut bacterial ecosystem is truly causal in this relationship, and thus whether reversal of antibiotic-mediated gut dysbiosis might prove beneficial in restoring full sensitivity to ICPI. Whether a favourable gut microbiota is a reflection of an otherwise healthy host rather than the *primum movens* of clinically meaningful anti-cancer immune responses is still the subject of intense debate \[[@CR13]\]. To this end, appreciating how antibiotics might dynamically affect such a strong immune-microbiologic correlate of response to checkpoint inhibition is of key importance to pave the way for strategies that could restore or protect the integrity of this important phenotypic correlate of response. To address the multiplicity of mechanisms that are likely to underscore this complex and bi-directional relationship, the coordinated study of a number of fundamental pathophysiologic processes including bacterial translocation, immune-modulation, an altered metabolome, enzymatic degradation and reduced diversity of the gut microbiome has been proposed as an overarching framework \[[@CR37]\].

Gaining sufficient insight as to the mode of action by which bacteria might work as biotherapeutic agents is not just important for patient prognostication, but is in fact key to a successful, rational development of microbiome-modulating therapies which improve patient's outcome with ICPI. With antibiotic use now having been validated as an important and dynamic factor influencing outcome from immunotherapy, concerted efforts should be aimed at characterizing the candidate taxonomic features in the gut microbiota that are associated with worse outcome from ICPI in the context of preceding and concomitant antibiotic exposure and evaluate them in conjunction with the concomitant prescription of proton pump inhibitors, corticosteroids and vaccines, all of which have been postulated to influence ICPI response \[[@CR38]\].

Recognising these changes is expected to facilitate the clinical development of diverse biotherapeutic approaches to induce microbiome reprogramming including dietary interventions with pre-biotics, therapeutic administration of single or multiple types of bacterial species or their metabolites, selective antibiotic therapy or faecal microbial transplantation, all of which are currently at the focus of intense clinical research efforts \[[@CR26]\].
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